Healthcare / Drug Manufacturers - Specialty & GenericJakarta
$1585.00
-10.00 (-0.63%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $93.9B · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
47/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.78T
P/E
12.7x
↓EV/EBITDA
5.5x
↓ROE
11.1%
↑Gross Margin
54.3%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
4.2%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.23T · net income $163.95B · FCF $93.86B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2231.75B | $2231.75B | $2087.60B | $1890.89B | $1917.04B |
| Net Income | $163.95B | $163.95B | $156.15B | $146.34B | $149.38B |
| EBITDA | $261.49B | $261.49B | $246.44B | $227.15B | $234.37B |
| EPS | — | — | 138.00 | 131.00 | 133.00 |
| Gross Margin | 54.3% | 54.3% | 52.5% | 51.6% | 52.5% |
| Operating Margin | 9.2% | 9.2% | 9.4% | 9.4% | 9.1% |
| Net Margin | 7.3% | 7.3% | 7.5% | 7.7% | 7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 2.35 | 2.35 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $93.86B | $93.86B | $229.11B | $11.27B | $-76.27B |
| Returns | |||||
| ROE | 11.1% | 11.1% | 10.8% | 10.4% | 10.6% |
| Valuation | |||||
| P/E | 12.67 | 12.67 | 11.56 | 12.94 | 17.59 |
| EV/EBITDA | 5.48 | 5.48 | 5.80 | 7.31 | 9.67 |
| P/B | 1.20 | 1.20 | 1.23 | 1.35 | 1.87 |
| Growth & Yield | |||||
| Revenue Growth | 6.9% | 6.9% | 10.4% | -1.4% | — |
| EPS Growth | — | — | 5.3% | -1.5% | — |
| Dividend Yield | 6.8% | 6.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.7%
Start / end P/E
n/dx → n/dx
EPS bridge
138.00 → n/d
Residual
-5.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.